Hagai is an Associate at aMoon Growth, where he draws on his scientific and industry background to source and evaluate late-stage investment opportunities in life science tools and diagnostics.
Before joining aMoon, Hagai built deep expertise across molecular diagnostics, therapeutics, and disease biology. He served as Platform Team Lead at 1E Therapeutics, spearheading the development of oligonucleotide-based therapies. Earlier, at Rosetta Genomics, he contributed to the full lifecycle of cancer diagnostic test development.
Hagai earned his MSc and PhD from the Weizmann Institute of Science, where his research uncovered novel mechanisms in ALS and was published in Molecular Cell. He then joined Massachusetts General Hospital and Harvard Medical School as a staff scientist, leading translational research efforts in neurodegeneration and pain.
